Inspection Record

Diplomat Pharmacy Inc. dba Diplomat Specialty Pharmacy — FDA 483 Findings

US FDAInspected 2018-01-05Published 2024-01-17 4 findingsAseptic processing and sterility assuranceOther quality system

Inspectors Emily J Orban · Bei Y HeThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Aseptic processing and sterility assurance

The ISO 5 classified aseptic processing areas had difficult to clean equipment or surface.

2Other quality system

Your firm released drug product in which the strength differs from, or its purity or quality falls below, that which it purports or is represented to possess.Your firm released drug product in which the strength differs from, or its purity or quality falls below, that which it purports or is represented to possess.

3Aseptic processing and sterility assurance

Disinfecting agents and cleaning wipes used in the ISO 5 classified aseptic processing areas were not sterile.

4Aseptic processing and sterility assurance

Inadequately protected product intended to be sterile was exposed to lower than ISO 5 classified aseptic processing area quality air.

About this record

Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Diplomat Pharmacy Inc. dba Diplomat Specialty Pharmacy company profile — full history US FDA documents, 2024 Go to Findings search